AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19892047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of autologous mononuclear bone marrow stem cells (BMSCs)
Number of subjects: 60
Study 19892047 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BMSCs)
Number of subjects: 60
Study 16500493 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography
Number of subjects: 24
Study 15342836 — intervention group
Group type: COMPARATOR
Intervention: Non-sleep-deprived (NSD) EEGs
Number of subjects: 820
Study 15342836 — intervention group
Group type: COMPARATOR
Intervention: Partially sleep-deprived (PSD) EEGs
Number of subjects: 820
Study 15342836 — intervention group
Group type: COMPARATOR
Intervention: Standard sleep-deprived (SSD) EEGs
Number of subjects: 820
Study 11032279 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT3 receptor antagonists
Number of subjects: 41
Study 11032279 — intervention group
Group type: COMPARATOR
Intervention: Traditional antiemetic agents (droperidol)
Number of subjects: 41
Study 11032279 — intervention group
Group type: COMPARATOR
Intervention: Traditional antiemetic agents (metoclopramide)
Number of subjects: 41
Study 9064405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of drugs (group IM)
Number of subjects: 176
Study 9064405 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (100%)
Number of subjects: 176
Study 9064405 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (74.2%)
Number of subjects: 176
Study 9064405 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol (60%)
Number of subjects: 176
Study 9064405 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple drugs (60%)
Number of subjects: 176
Study 9064405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 176
Study 1338319 — intervention group
Group type: EXPERIMENTAL
Intervention: D-F 15 mg b.d. for 26 weeks
Number of subjects: 45
Study 1338319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 1338319 — intervention group
Group type: EXPERIMENTAL
Intervention: D-F
Number of subjects: 45
Study 1338319 — intervention group
Group type: EXPERIMENTAL
Intervention: D-F (after switching from placebo)
Number of subjects: 45
Study 6707231 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg codeine
Number of subjects: 108
Study 6707231 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg acetaminophen
Number of subjects: 108
Study 6707231 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen
Number of subjects: 108
Study 30921187 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 98
Study 30921187 — intervention group
Group type: COMPARATOR
Intervention: Standardized medical treatment
Number of subjects: 98
Study 29129600 — intervention group
Group type: EXPERIMENTAL
Intervention: MABp1
Number of subjects: 20
Study 29129600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26794722 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (early coronary angiography with immediate assessment for percutaneous coronary intervention, coronary artery bypass graft, and optimum medical treatment)
Number of subjects: 457
Study 26794722 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (optimum medical treatment alone)
Number of subjects: 457
Study 26794722 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 457
Study 26794722 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 457
Study 24886352 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 1.5 hour weight management group until 6 weeks postpartum, combining Slimming World expertise with NHS midwives' clinical advice.
Number of subjects: 570
Study 24886352 — intervention group
Group type: COMPARATOR
Intervention: Usual care and two leaflets giving advice on diet and physical activity.
Number of subjects: 570
Study 23181339 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) intervention, conducted in a home-based setting, for six weeks, twice a week.
Number of subjects: 0
Study 23181339 — intervention group
Group type: COMPARATOR
Intervention: Placebo training intervention, conducted in a home-based setting, for six weeks, after a two-week washout period, twice a week.
Number of subjects: 0
Study 20103032 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink (250 mL, sugar-free)
Number of subjects: 50
Study 20103032 — intervention group
Group type: COMPARATOR
Intervention: Control (no energy drink)
Number of subjects: 50
Study 17669707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fine-needle aspiration (FNA) with measurement of parathyroid hormone (PTH) in the aspirate
Number of subjects: 34
Study 17669707 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive parathyroidectomy (MIP)
Number of subjects: 34
Study 17669707 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative follow-up
Number of subjects: 34
Study 17669707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fine-needle aspiration (FNA)
Number of subjects: 34
Study 16284381 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO) plus triamcinolone
Number of subjects: 124
Study 16284381 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO) plus placebo
Number of subjects: 124
Study 16284381 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo plus triamcinolone
Number of subjects: 124
Study 16284381 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 124
Study 11893781 — intervention group
Group type: EXPERIMENTAL
Intervention: Stick margarine diet (30% of calories as fat)
Number of subjects: 19
Study 11893781 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil diet (30% of calories as fat)
Number of subjects: 19
Study 11893781 — intervention group
Group type: COMPARATOR
Intervention: Butter diet (30% of calories as fat)
Number of subjects: 19
Study 10457875 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol drops 1.5 mg kg-1 (n = 31)
Number of subjects: 60
Study 10457875 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) (n = 29)
Number of subjects: 60
Study 10432161 — intervention group
Group type: EXPERIMENTAL
Intervention: 72-hour intravenous tubing set changes
Number of subjects: 2213
Study 10432161 — intervention group
Group type: COMPARATOR
Intervention: 24-hour intravenous tubing set changes
Number of subjects: 2213
Study 2173390 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectin-enriched cereal
Number of subjects: 58
Study 2173390 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium-enriched cereal
Number of subjects: 58
Study 2173390 — intervention group
Group type: COMPARATOR
Intervention: Diet-only phase
Number of subjects: 58
Study 330480 — intervention group
Group type: COMPARATOR
Intervention: 375 mg amoxycillin three times daily
Number of subjects: 298
Study 330480 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pivmecillinam three times daily
Number of subjects: 298
Study 330480 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg pivmecillinam three times daily
Number of subjects: 298
Study 30948254 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic tourniquet (ET)
Number of subjects: 121
Study 30948254 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure cuff (BPC)
Number of subjects: 121
Study 28257752 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib plus ofatumumab (oral idelalisib 150 mg twice daily continuously plus ofatumumab 300 mg intravenously in week 1, then 1000 mg intravenously weekly for 7 weeks, and every 4 weeks for 16 weeks)
Number of subjects: 261
Study 28257752 — intervention group
Group type: COMPARATOR
Intervention: Ofatumumab alone (ofatumumab dosing as per the combination group, except 2000 mg was substituted for the 1000 mg dose)
Number of subjects: 261
Study 28257752 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib plus ofatumumab
Number of subjects: 261
Study 28257752 — intervention group
Group type: COMPARATOR
Intervention: Ofatumumab
Number of subjects: 261
Study 25981401 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (1 day prior to NSS and 2 days following surgery)
Number of subjects: 49
Study 25981401 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tadalafil treatment)
Number of subjects: 49
Study 24075657 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia information (DVD) plus verbal information
Number of subjects: 90
Study 24075657 — intervention group
Group type: COMPARATOR
Intervention: Verbal information alone
Number of subjects: 90
Study 21810659 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent
Number of subjects: 300
Study 21810659 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent
Number of subjects: 300
Study 19253237 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost 0.0015% (once daily) with timolol 0.5% (twice daily)
Number of subjects: 185
Study 19253237 — intervention group
Group type: COMPARATOR
Intervention: Vehicle with timolol 0.5% (twice daily)
Number of subjects: 185
Study 19253237 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost after switching from vehicle
Number of subjects: 185
Study 19253237 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost
Number of subjects: 185
Study 17092274 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing positive images of dentistry
Number of subjects: 38
Study 17092274 — intervention group
Group type: COMPARATOR
Intervention: Dentally neutral images (Control)
Number of subjects: 38
Study 15349735 — intervention group
Group type: EXPERIMENTAL
Intervention: Short battery consisting of two bedside tests
Number of subjects: 40
Study 15349735 — intervention group
Group type: EXPERIMENTAL
Intervention: Short battery consisting of two bedside tests (with changed criteria)
Number of subjects: 40
Study 15349735 — intervention group
Group type: COMPARATOR
Intervention: 45-min neuropsychological screening battery (gold standard)
Number of subjects: 40
Study 11323730 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 15
Study 11323730 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 15
Study 11323730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9468460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CsA; 10 mg/kg)
Number of subjects: 18
Study 8560834 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 400 mg perorally, given one day prior to operation and continued daily for three months
Number of subjects: 15
Study 8560834 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen treatment
Number of subjects: 15
Study 2884190 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifentidine (10 mg)
Number of subjects: 10
Study 2884190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29174109 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D of AS04-HPV-16/18
Number of subjects: 1075
Study 29174109 — intervention group
Group type: COMPARATOR
Intervention: 2D of 4vHPV
Number of subjects: 1075
Study 29174109 — intervention group
Group type: COMPARATOR
Intervention: 3D of 4vHPV
Number of subjects: 1075
Study 26718605 — intervention group
Group type: COMPARATOR
Intervention: IV delafloxacin (300 mg)
Number of subjects: 130
Study 26718605 — intervention group
Group type: COMPARATOR
Intervention: Oral delafloxacin (450 mg)
Number of subjects: 130
Study 25754300 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral economics strategies during home dinner meal occasions for 6 weeks
Number of subjects: 46
Study 25754300 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study 22340966 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT (1:1 allocation); one 90 min session a week for 6 weeks.
Number of subjects: 96
Study 22340966 — intervention group
Group type: COMPARATOR
Intervention: Usual care; control group.
Number of subjects: 96
Study 21092137 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (Coartem®)
Number of subjects: 470
Study 21092137 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate plus mefloquine (Artequin™)
Number of subjects: 470
Study 18536065 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 0
Study 15960642 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2% 0.75 ml.kg(‐1)
Number of subjects: 75
Study 15960642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% 0.75 ml.kg(‐1) plus clonidine 1 microg.kg(‐1)
Number of subjects: 75
Study 15960642 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% 0.75 ml.kg(‐1) plus ketamine 0.5 mg.kg(‐1)
Number of subjects: 75
Study 12610006 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 448
Study 12610006 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 448
Study 10348223 — intervention group
Group type: EXPERIMENTAL
Intervention: Malarone (250 mg of atovaquone/100 mg of proguanil hydrochloride per tablet)
Number of subjects: 274
Study 10348223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 7491835 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol matrix patch (0.05 mg/day)
Number of subjects: 166
Study 7491835 — intervention group
Group type: COMPARATOR
Intervention: Oral conjugated equine estrogens (0.625 mg/day)
Number of subjects: 166
Study 7491835 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol matrix patch
Number of subjects: 166
Study 7491835 — intervention group
Group type: COMPARATOR
Intervention: Oral conjugated equine estrogens
Number of subjects: 166
Study 7491835 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 166
Study 1781046 — intervention group
Group type: EXPERIMENTAL
Intervention: DBCG 77a (1977‐1982)
Number of subjects: 7315
Study 1781046 — intervention group
Group type: EXPERIMENTAL
Intervention: DBCG 82a (1982‐1990)
Number of subjects: 7315
Study 161858 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive containing 0.05 mg of ethinylestradiol and 0.100 mg or 0.125 mg of a new progestogen (17 alpha‐ethinyl‐18‐methylene‐4‐estren‐17 beta‐ol)
Number of subjects: 7
Study 161858 — intervention group
Group type: COMPARATOR
Intervention: Control cycle
Number of subjects: 7
Study 30989638 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-metaphoric description of plagiarism
Number of subjects: 365
Study 30989638 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 365
Study 31172416 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated-interferon (peg-IFN) consolidation treatment for 48 weeks
Number of subjects: 48
Study 31172416 — intervention group
Group type: COMPARATOR
Intervention: nucleos(t)ide analogue (NA) consolidation treatment for 48 weeks
Number of subjects: 48
Study 28857592 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interventions
Number of subjects: 1512
Study 28857592 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity interventions
Number of subjects: 1512
Study 28857592 — intervention group
Group type: COMPARATOR
Intervention: Standard cases (St)
Number of subjects: 1512
Study 28857592 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex cases (Cx)
Number of subjects: 1512
Study 26156667 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthesized right-sided chest ECG (Syn-ECG)
Number of subjects: 30
Study 26156667 — intervention group
Group type: EXPERIMENTAL
Intervention: New criteria from Syn-ECG
Number of subjects: 30
Study 23364679 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 15
Study 23364679 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study 21908720 — intervention group
Group type: EXPERIMENTAL
Intervention: Characterized chondrocyte implantation (CCI)
Number of subjects: 112
Study 21908720 — intervention group
Group type: COMPARATOR
Intervention: Microfracture (MF)
Number of subjects: 112
Study 19628801 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Process Training (APT)
Number of subjects: 78
Study 19628801 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 78
Study 17083722 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-initiated preconception counselling (PCC)
Number of subjects: 1656
Study 17083722 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 1656
Study 15255491 — intervention group
Group type: EXPERIMENTAL
Intervention: Municipality intervention with education for primary care professionals and GPs' short assessment programme
Number of subjects: 4060
Study 15255491 — intervention group
Group type: EXPERIMENTAL
Intervention: Accepting and receiving free preventive home visits
Number of subjects: 4060
Study 11235127 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency ambulance utilization
Number of subjects: 2294
Study 11235127 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for requesting EA
Number of subjects: 2294
Study 11235127 — intervention group
Group type: EXPERIMENTAL
Intervention: Improper use of EA
Number of subjects: 2294
Study 11235127 — intervention group
Group type: EXPERIMENTAL
Intervention: Regulatory compliance of EA use
Number of subjects: 2294
Study 9306146 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress imaging with Tc‐99m MIBI SPECT
Number of subjects: 460
Study 8379288 — intervention group
Group type: EXPERIMENTAL
Intervention: Bair Hugger
Number of subjects: 60
Study 8379288 — intervention group
Group type: COMPARATOR
Intervention: Reflective blanket
Number of subjects: 60
Study 8379288 — intervention group
Group type: COMPARATOR
Intervention: Humidistat
Number of subjects: 60
Study 8379288 — intervention group
Group type: COMPARATOR
Intervention: Heated humidifier
Number of subjects: 60
Study 31649349 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear lens extraction (CLE)
Number of subjects: 0
Study 31649349 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic laser peripheral iridotomy (PI)
Number of subjects: 0
Study 29962050 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks (Q2W)
Number of subjects: 100
Study 29962050 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg every month (QM)
Number of subjects: 100
Study 29962050 — intervention group
Group type: COMPARATOR
Intervention: Placebo Q2W
Number of subjects: 100
Study 29962050 — intervention group
Group type: COMPARATOR
Intervention: Placebo QM
Number of subjects: 100
Study 26862823 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (8 weekly sessions)
Number of subjects: 110
Study 26862823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychoeducational intervention)
Number of subjects: 110
Study 26862823 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall allograft survival rate
Number of subjects: 110
Study 24827879 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-initiated AF clinical pathway with early follow-up in a specialty AF outpatient clinic
Number of subjects: 100
Study 22902422 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial silicon retina (ASR) implantation
Number of subjects: 8
Study 20122306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group membership primed with increasing group size
Number of subjects: 0
Study 20122306 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagining others as women
Number of subjects: 0
Study 20122306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group size increase
Number of subjects: 0
Study 16403233 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cimetidine 800 mg per day
Number of subjects: 80
Study 16403233 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral omeprazole 40 mg per day
Number of subjects: 80
Study 15569787 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic stibogluconate
Number of subjects: 114
Study 15569787 — intervention group
Group type: COMPARATOR
Intervention: Branded pentavalent antimony (Pentostam or Glucantime)
Number of subjects: 114
Study 11672550 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinyl estradiol/100 microg levonorgestrel (LNG)
Number of subjects: 704
Study 11672550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study 9427888 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E prophylaxis
Number of subjects: 704
Study 9427888 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 704
Study 8499355 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoromethalone 0.1%
Number of subjects: 2
Study 8499355 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1%
Number of subjects: 2
Study 8499355 — intervention group
Group type: COMPARATOR
Intervention: Both twins on identical tapering regimen of corticosteroids over 3 months
Number of subjects: 2
Study 3318799 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.6 mg with d-amphetamine 5 mg
Number of subjects: 0
Study 3318799 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 0.6 mg with d-amphetamine 5 mg and neostigmine 15 mg
Number of subjects: 0
Study 3318799 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 15 mg
Number of subjects: 0
Study 3318799 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion sickness (induced by head movements in a rotating chair)
Number of subjects: 0
Study 3318799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29167081 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg crossing and muscle tensing technique during PIV placement
Number of subjects: 28
Study 29167081 — intervention group
Group type: COMPARATOR
Intervention: Standard care during PIV placement
Number of subjects: 28
Study 29167081 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg crossing and muscle tensing technique
Number of subjects: 28
Study 29167081 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 28
Study 26568469 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive home visit
Number of subjects: 459
Study 26568469 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiprofessional senior group meetings
Number of subjects: 459
Study 24884501 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic FLOX + cetuximab
Number of subjects: 504